Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis . Official document of the Brazilian Thoracic Association based on the GRADE methodology by Baddini-Martinez, José et al.
ISSN 1806-3713© 2020 Sociedade Brasileira de Pneumologia e Tisiologia
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown 
cause, which predominantly affects elderly men who are current or former smokers. 
Even though it is an uncommon disease, it is of great importance because of its severity 
and poor prognosis. In recent decades, several pharmacological treatment modalities 
have been investigated for the treatment of this disease, and the classic concepts have 
therefore been revised. The purpose of these guidelines was to define evidence-based 
recommendations regarding the use of pharmacological agents in the treatment of IPF in 
Brazil. We sought to provide guidance on the practical issues faced by clinicians in their 
daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and 
Outcome of interest (PICO)-style questions were formulated to address aspects related 
to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, 
endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and 
nintedanib. To formulate the PICO questions, a group of Brazilian specialists working 
in the area was assembled and an extensive review of the literature on the subject was 
carried out. Previously published systematic reviews with meta-analyses were analyzed 
for the strength of the compiled evidence, and, on that basis, recommendations were 
developed by employing the Grading of Recommendations Assessment, Development 
and Evaluation approach. The authors believe that the present document represents an 
important advance to be incorporated in the approach to patients with IPF, aiming mainly 
to improve its management, and can become an auxiliary tool for defining public policies 
related to IPF.
Keywords: Idiopathic pulmonary fibrosis; GRADE approach; Pulmonary fibrosis/drug 
therapy; Practice guideline.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a form of chronic 
interstitial lung disease of unknown cause, limited to 
the lungs, which predominantly affects elderly men who 
are current or former smokers.(1-5) From a histological 
standpoint, IPF is characterized by the usual interstitial 
pneumonia pattern that can currently be inferred with 
a reasonable degree of certainty in cases of typical 
radiological findings on HRCT.(1-5) Even though it is an 
uncommon disease, IPF is of great clinical importance 
because of its severity. Although the natural history 
of the disease may vary and it is difficult to make 
accurate prognostic predictions for a given patient, 
the median survival for untreated patients with IPF is 
only 2.9 years.(6)
In recent decades, several pharmacological treatment 
modalities, with varied mechanisms of action, have been 
investigated for the treatment of IPF, and a substantial 
number of studies have reported negative outcomes. (7-36) 
Nevertheless, new drugs have shown benefits for the 
1. Faculdade de Medicina de Ribeirão 
Preto, Universidade de São Paulo, 
Ribeirão Preto (SP) Brasil.
2. Escola Paulista de Medicina, 
Universidade Federal de São Paulo,  
São Paulo (SP) Brasil.
3. Faculdade de Medicina, Universidade de 
São Paulo, São Paulo (SP) Brasil.
4. Faculdade de Medicina de Botucatu, 
Universidade Estadual Paulista – 
UNESP – Botucatu (SP) Brasil.
5. Universidade Católica de Brasília, 
Brasília (DF) Brasil.
6. Universidade do Estado do Rio de 
Janeiro – UERJ – Rio de Janeiro (RJ) 
Brasil.
7. Universidade Federal do Rio Grande do 
Sul – UFRGS – Porto Alegre (RS) Brasil.
8. Hospital Geral Roberto Santos,  
Salvador (BA) Brasil.
9. Instituto de Pesquisa. Hospital do 
Coração, São Paulo (SP) Brasil.
10. Universidade Federal do Ceará, 
Fortaleza (CE) Brasil.
11. Universidade Federal de Minas Gerais, 
Belo Horizonte (MG) Brasil.
12. Universidade Federal de Goiás,  
Goiânia (GO) Brasil.
13. Universidade de Brasília – UnB – 
Brasília (DF) Brasil.
14. Hospital do Servidor Público Estadual 
de São Paulo, São Paulo (SP) Brasil.
15. Universidade Federal de Ciências da 
Saúde de Porto Alegre, Porto Alegre 
(RS) Brasil.
16. Universidade Federal de Santa Catarina 
– UFSC – Florianópolis (SC) Brasil.
17. Universidade Federal do Paraná – 
UFPR – Curitiba (PR) Brasil.
Submitted: 20 December 2019.
Accepted: 12 January 2020.
Study carried out by the Sociedade 




J Bras Pneumol. 2020;46(2):e20190423
SPECIAL ARTICLE
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis.
Official document of the Brazilian Thoracic Association based on the GRADE methodology
treatment of this disease, and some of them are already 
commercially available for this indication.
The purpose of these guidelines was to define 
evidence-based recommendations regarding the use 
of pharmacological agents in the treatment of IPF. We 
sought to provide guidance on the practical issues faced 
by clinicians in their daily routine. To that end, we 
carried out an extensive review of the literature on the 
subject, employing the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach.(37) It should be noted that, to date, there 
have been no studies using a methodology similar 
to that employed here to address the topic in Brazil.
METHODOLOGY
The development of the guidelines began with the 
formation of a group of coordinators, which included 
two recognized specialists in the subject area and 
two specialists in methodology. Pulmonologists 
familiar with the care of patients with IPF, working 
in different regions of Brazil, were invited to join a 
specialist committee. Everyone involved in the process 
provided signed conflict-of-interest forms (Chart S1, 
supplementary material: http://jornaldepneumologia.
com.br/detalhe_anexo.asp?id=73).
In a face-to-face meeting, held in September of 2017 
in the city of São Paulo, Brazil, the objectives of the 
project were defined. It was decided that the GRADE 
approach would be used and that priority would be 
given to questions related only to the pharmacological 
treatment of IPF. The specialists then received written 
materials and training videos related to each step of 
the GRADE approach.(38-40)
The specialists formulated Patients of interest, 
Intervention to be studied, Comparison of intervention 
and Outcome of interest (PICO)-style questions related 
to the pharmacological treatment of patients with IPF. 
Through an online voting process, seven PICO questions 
and their corresponding highest-scored outcomes were 
selected on the basis of degree of importance. The 
outcomes were classified as unimportant, important, or 
critical, taking into account the IPF patient perspective, 
in accordance with the GRADE approach (Chart 1).
A librarian searched for articles published in English 
in PubMed and EMBASE, following a standardized 
methodology, under the supervision of the methodologists 
(Chart S2). In our search strategy, we focused on 
systematic reviews with meta-analyses, using pre-
established keywords and covering a period of 10 years 
or less, with an inclusion data limit of November 2018. 
A decision was made to employ a pragmatic strategy 
of searching for completed meta-analyses, rather than 
searching for clinical trials and subsequently performing 
meta-analyses.
After the preliminary selection of articles, the 
methodologists separately evaluated the articles by 
reviewing their titles and abstracts to decide which ones 
would be included in the guidelines. Disagreements were 
resolved by consensus. The next step involved qualitative 
analysis of the full texts of the selected articles, which 
was carried out by the two methodologists, working 
independently. Again, disagreements about inclusion or 
exclusion of articles were resolved by consensus. The 
selected articles were then evaluated by the specialist 
coordinators, each working separately, and agreement 
among the analyses regarding the inclusion or exclusion 
of articles was assessed. The reasons for excluding 
articles, as presented in Figures S1 through S7 of the 
supplementary material, were documented in accordance 
with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) recommendations.(41)
Tables summarizing the evidence for each question 
(Tables S1 through S7) were prepared following the 
GRADE approach, using the GRADEpro Guideline 
Chart 1. Questions and corresponding outcomes selected for the development of these guidelines.
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IPF: idiopathic pulmonary fibrosis.
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Development Tool (GDT; McMaster University, 
HamiltonON, Canada).(42) The quality of the evidence 
for each meta-analysis included, as a function of each 
analyzed outcome, was classified as high, moderate, 
low, or very low (Chart 2).
The quality of evidence was reduced by one or two 
grades if a risk of bias, indirect evidence, inconsistency, 
imprecision, or publication bias was identified. In 
contrast, the quality of evidence was upgraded if there 
was a strong association, no plausible confounders, 
or a dose response relationship, or if all plausible 
confounders would have reduced the effect (Chart 
3). In the GRADE approach, the quality of the studies 
determines the confidence level and degree of certainty 
of the estimated effect of the intervention on each of 
the outcomes selected.(40)
In September of 2019, the Coordinating Committee 
met face to face with the specialists, in the city of São 
Paulo, to review the results and all tables summarizing 
the evidence. The attending members reviewed the 
tables, and corrections were made as appropriate.
Recommendations based on critical outcomes were 
made for each question, following the GRADE approach 
(Chart 4). When there was no consensus, votes 
were taken, the results of which were documented 
(Chart S3). The recommendations could be either 
strong or conditional.(40) The term “we recommend” was 
used for strong recommendations, and the term “we 
suggest” was used for conditional recommendations. 
Factors influencing the strength of recommendation 
included the balance between benefits and undesirable 
consequences, the overall quality of evidence, patient 
values/preferences, costs, and resource allocation.
For the preparation of the manuscript, the text 
was divided among the participants, each of whom 
returned their sections to the specialist coordinators 
within certain deadlines. A preliminary version of 
the guidelines was then edited and sent to all of the 
participants for corrections and suggestions, in an 
interactive process. All of the individuals listed as 
authors take responsibility for the final text, in its 
entirety. The seven PICO questions, as well as the 
evidence, recommendations, and comments related 
to them, are described below.
QUESTION 1: SHOULD WE RECOMMEND 
THE USE OF NINTEDANIB FOR PATIENTS 
WITH IPF?
Nintedanib was initially developed as an inhibitor 
of VEGF and FGF receptors, being intended for use in 
the treatment of cancer.(43) However, since nintedanib 
inhibits PDGF receptors, it has also been investigated 
as a therapy for IPF.(43) Nintedanib competitively 
inhibits tyrosine kinases, which explains its many 
potential actions, such as impeding the migration and 
proliferation of myofibroblasts and fibroblasts, as well 
as the deposition of extracellular matrix. In addition, 
more recent evidence indicates that nintedanib can 
reduce TGF-β production, inhibit the formation of 
the collagen fibrin network, and stimulate surfactant 
protein D production.(44-46)
Chart 2. Quality of evidence interpretation following the Grading of Recommendations Assessment, Development and 
Evaluation system.a
Quality of evidence Implication Example
High ⨁⨁⨁⨁ Further research is very unlikely to change 
our confidence in the estimate of effect; 
we are confident that we can expect a very 
similar effect in the population for which the 
recommendation is intended
Randomized trials without serious limitations
Well-performed observational studies with very 
large effects 
Moderate ⨁⨁⨁◯ Further research is likely to have an important 
impact on our confidence in the estimate of 
effect and may change the estimate
Randomized trials with serious limitations
Well-performed observational studies yielding 
large effects
Low ⨁⨁◯◯ Further research is very likely to have a major 
impact on our confidence in the estimate of 
effect and is likely to change the estimate
Randomized trials with very serious limitations
Observational studies without special 
strengths or important limitations
Very low ⨁◯◯◯ Any estimate of effect is very uncertain Randomized trials with very serious limitations 
and inconsistent results
Observational studies with serious limitations
Unsystematic clinical observations (e.g., case 
series or case reports)
aAdapted from the Brazilian National Ministry of Health.(37)
Chart 3. Factors that can affect the quality of evidence.a
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• A strong association, with no plausible confounders
• Evidence of dose response
• All plausible confounders would have reduced the effect
aAdapted from Guyatt et al.(38)
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One phase II clinical trial and two phase III clinical 
trials, all observing subjects over a one-year period, 
evaluated the effects that nintedanib at a target dose 
of 150 mg twice daily had on the rate of decline in 
FVC.(27,28) On the basis of the results observed for this 
primary outcome, the US Food and Drug Administration 
approved nintedanib for use in patients with IPF.(47) 
The most common adverse effects of nintedanib, 
when it is used at the doses recommended for the 
treatment of IPF, are related to the gastrointestinal 
tract, especially diarrhea, of varying intensity, which, 
in the original clinical trials, affected approximately 
62% of the participants who used the drug.(28)
Evidence
Using the methodology described above, we 
selected six systematic reviews with meta-analyses 
(Figure S1). (48-55) Even though not all of them analyzed 
the exact same sets of outcomes, they all indicate 
a beneficial therapeutic effect of nintedanib versus 
placebo in patients with IPF (Table S1).
With regard to mortality (a critical outcome), there 
was no statistically significant effect (OR = 0.70; 
95% CI: 0.45-1.09) and the quality of evidence was 
moderate.(48)
With regard to a decline in FVC (a critical outcome), 
nintedanib was found to be beneficial. For a > 10% 
decline in FVC, the estimated OR was 0.61 (95% CI: 
0.48-0.78), indicating a high quality of evidence.(48)
Finally, with regard to number of exacerbations (a 
critical outcome), nintedanib was found to be effective 
in reducing the number of acute exacerbations (OR 
= 0.50; 95% CI: 0.31-0.79), indicating a moderate 
quality of evidence.(54)
Recommendation
For patients with IPF, we suggest using nintedanib 
(conditional recommendation; moderate quality of 
evidence).
Comments
The available meta-analyses included only randomized, 
double-blind, controlled clinical trials. Therefore, 
the results obtained apply primarily to patients who 
meet the same selection criteria as those used for 
the participants in those trials. Those trials did not 
include patients with very early-stage IPF (DLCO ≥ 
80%) or very advanced IPF (FVC < 50% of predicted 
or DLCO < 30%). 
Therefore, the effects of nintedanib in these two 
groups of patients have yet to be well characterized. 
In addition, it is not possible to determine, on the basis 
of the selected articles, the long-term efficacy and 
safety of nintedanib, because the maximum duration 
of the trials included here was 52 weeks.
The recommendation made implies that using 
nintedanib is the right course of action to be taken in 
50-95% of cases.(42) Clinicians should acknowledge 
that different choices may be appropriate for individual 
patients and that they are responsible for helping 
patients and families make decisions consistent with 
their values and preferences (Chart 4).(37-42) This 
recommendation does not take into account cost 
analyses or aspects of drug economics.
QUESTION 2: SHOULD WE RECOMMEND 
THE USE OF PIRFENIDONE FOR PATIENTS 
WITH IPF?
Pirfenidone is a drug with anti-inflammatory and 
antifibrotic properties that acts through regulation 
of TNF-α and TGF-β pathways, as well as through 
modulation of cellular oxidation.(56) Ultimately, 
pirfenidone inhibits fibroblast proliferation, consequently 
decreasing collagen synthesis and deposition.(56-59)
The therapeutic potential of pirfenidone was initially 
demonstrated in two small clinical trials, which compared 
it with placebo.(16,20) Subsequently, three other clinical 
trials stood out for greater homogeneity of inclusion 
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intervention to be 
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Most patients should receive the recommended 
intervention
The health professional should acknowledge 
that different choices may be appropriate for 
individual patients and should help them make 
a decision consistent with their values and 
preferences
Administrators The recommendation can be adopted as a health 
policy in most situations
Substantial debate and involvement of all 
stakeholders are required
aAdapted from Guyatt et al.(39) and Andrews et al.(40)
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criteria and outcomes, including assessment of > 
10% decline in FVC at week 52.(25,26) Those three 
clinical trials, in a combined analysis, demonstrated a 
reduced decline in percentage predicted FVC, as well 
as a reduced risk of disease progression, with the use 
of a target dose of 2,403 mg/day. In the five clinical 
trials, adverse events were more common in the group 
receiving pirfenidone, being mainly related to the skin 
(rash and photosensitivity) and the gastrointestinal 
tract (nausea, dyspepsia, and loss of appetite).
Evidence
Nine systematic reviews with meta-analyses 
comparing pirfenidone with placebo were selected 
(Figure S2).(55,60-65) The meta-analyses evaluated 
several outcomes, including mortality, progression-free 
survival, acute exacerbation, functional decline, change 
in six-minute walk distance (6MWD), and adverse 
events, indicating that pirfenidone has a favorable 
therapeutic effect and an acceptable safety profile.
Table S2 summarizes the quality of evidence of 
the selected articles for the question related to 
pirfenidone. Pirfenidone treatment was shown to 
reduce mortality—relative risk (RR) = 0.53; 95% 
CI: 0.32-0.88, indicating a moderate quality of 
evidence. (61,62) Likewise, pirfenidone was found to 
be effective in reducing the occurrence of a > 10% 
decline in FVC (RR = 0.64; 95% CI: 0.50-0.83).(61,62) 
With regard to the reduction in the number of acute 
exacerbations, there was no statistically significant 
effect (RR = 0.59; 95% CI: 0.19-1.84), indicating a 
low quality of evidence.(61,62)
Recommendation
For patients with IPF, we suggest using pirfenidone 
(conditional recommendation; low quality of evidence).
Comments
The available systematic reviews and meta-analyses 
evaluating the use of pirfenidone in patients with IPF 
included only randomized, double-blind, controlled 
clinical trials. The results obtained apply to patients 
who meet the same selection criteria as those used 
for the participants in those trials, that is, patients 
with mild to moderate disease. Those trials did not 
include IPF patients who had very early-stage functional 
changes (DLCO ≥ 90%), had very advanced functional 
changes (FVC < 50% of predicted or DLCO < 30%), 
or were over 80 years of age. Therefore, the effects 
of pirfenidone in those subgroups of patients have 
yet to be determined. On the basis of the results 
found, it is not possible to determine the impact of 
pirfenidone in terms of long-term efficacy and safety, 
because the maximum duration of the trials included 
here was 72 weeks.
The recommendation made implies that using 
pirfenidone is the right course of action in 50-95% of 
cases.(42) Clinicians should acknowledge that choices 
need to be individualized and that they should help 
patients and their families make decisions consistent 
with their values and preferences (Chart 4).(37-42) This 
recommendation does not take into account cost 
analyses or aspects of drug economics.
QUESTION 3: SHOULD WE RECOMMEND 
THE USE OF PHOSPHODIESTERASE-5 
INHIBITORS FOR PATIENTS WITH IPF?
Phosphodiesterase-5 (PDE5) inhibitors stabilize cyclic 
guanosine monophosphate, the second messenger of 
nitric oxide, leading to pulmonary vasodilation.(66) The 
vasodilation produced by PDE5 inhibitors appears to 
have a preference for well-ventilated lung tissue, which 
could improve the ventilation-perfusion ratio and gas 
exchange in patients with IPF.(66) In addition, pulmonary 
hypertension is a common finding in patients with IPF, 
being associated with higher rates of morbidity and 
mortality.(67) The commercially available PDE5 inhibitors 
are sildenafil, tadalafil, and vardenafil; however, only 
sildenafil has been tested in patients with IPF.
Three clinical trials, of which only two were 
randomized, have evaluated the effects of sildenafil in 
patients with advanced IPF.(68-70) The primary outcome 
used was always a change in the 6MWD, which was 
not achieved in any of the investigations. Sildenafil 
treatment also had no impact on exacerbation or 
mortality rates.
Evidence
As a result of the methodology employed for these 
guidelines, two systematic reviews with meta-analyses 
were selected (Figure S3 and Table S3). One of those 
reviews found no evidence that sildenafil can provide 
relief of dyspnea in patients with IPF (relative risk 
not estimable; very low level of evidence) or improve 
quality of life in patients with IPF (relative risk not 
estimable; very low level of evidence).(71) The other 
meta-analysis, which used a network methodology, 
evaluated the effects of sildenafil treatment on mortality 
in patients with IPF, thus finding that the death rates 
in the treatment group and placebo group were 2.9% 
and 8.5%, respectively.(55) However, the OR was 0.84 
and did not reach statistical significance (95% CI: 
0.31-2.41).
Recommendation
For patients with IPF, we suggest not using a PDE5 
inhibitor (conditional recommendation; moderate 
quality of evidence).
Comments
The critical outcome selected for this question by the 
specialists working on these guidelines was mortality. 
With regard to this parameter, the selected articles 
did not show significant benefits of PDE5 inhibitors. 
The same was true for two outcomes classified as 
important: dyspnea and quality of life. It is of note that 
other guidelines for the treatment of IPF, developed by 
other medical societies, also do not recommend the 
use of a PDE5 inhibitor (sildenafil) for this group of 
patients.(4,72,73) In addition, a randomized clinical trial 
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comparing the use of nintedanib plus sildenafil with that 
of nintedanib alone in patients with IPF and a DLCO 
< 35% of the predicted value, which was published 
after the analysis of the articles selected for these 
guidelines had been completed, found no significant 
differences regarding quality of life or dyspnea.(34) A 
pre-specified analysis of the subgroup of patients with 
right ventricular dysfunction, published separately, 
also showed no impact on the relevant variables.(74)
QUESTION 4: SHOULD WE RECOMMEND 
THE USE OF ENDOTHELIN-RECEPTOR 
ANTAGONISTS FOR PATIENTS WITH IPF?
Although the pathogenesis of IPF has yet to be fully 
elucidated, endothelin-1, a potent vasoconstrictor and 
growth factor, has been related to the fibroproliferative 
process of IPF.(75) Endothelins have a potent 
proliferative effect on mesenchymal cells and can 
induce cell differentiation, increasing the synthesis 
and deposition of extracellular matrix components, 
as well as their contractility.(75) On the basis of 
these elements, clinical trials of endothelin-receptor 
antagonists have been conducted with the aim of 
reducing the fibrotic process.
Two clinical trials have evaluated the efficacy of 
bosentan versus that of placebo in patients with IPF. No 
significant effects of bosentan were detected, either on 
the primary outcome (6MWD) or on the rate of disease 
progression, quality of life, or dyspnea intensity.(18,22,76)
The effect of macitentan on the rate of decline in 
FVC in patients with IPF was also not significant in 
comparison with that of a placebo.(24) Finally, one study 
investigating the effects of ambrisentan versus those 
of placebo in patients with IPF was terminated early 
because an interim analysis showed that ambrisentan-
treated patients were more likely to meet the criteria 
for disease progression and had a greater number of 
respiratory hospitalizations.(23)
Evidence
Using the methodology proposed above, we selected 
two review articles with meta-analyses (Figure S4). Both 
evaluated individual results for bosentan, macitentan, 
and ambrisentan.(48,55) None of the drugs investigated 
showed significant effects with regard to mortality 
(critical outcome) or adverse effects (unimportant 
outcome; Table S4).
Recommendation
For patients with IPF, we recommend not 
using endothelin-receptor antagonists (strong 
recommendation; low quality of evidence).
Comments
In addition to the fact that the available evidence 
indicates no significant effects of endothelin-receptor 
antagonists on relevant clinical outcomes, it has been 
suggested that the use of ambrisentan, in particular, is 
associated with deleterious effects. It is unlikely that 
further studies of this class of drugs in patients with 
IPF will be conducted.
QUESTION 5: SHOULD WE RECOMMEND 
PHARMACOLOGICAL TREATMENT OF 
GASTROESOPHAGEAL REFLUX FOR 
PATIENTS WITH IPF?
Gastroesophageal reflux (GER) is highly prevalent 
in patients with IPF and, although there is as yet no 
evidence of a causal relationship, chronic aspiration 
is considered a risk factor for disease progression 
and exacerbation.(77-79) Although the importance of 
microaspiration of gastric content in the pathogenesis 
of IPF has yet to be established, there have been 
anecdotal reports of stabilization and (clinical and 
functional) improvement in patients with IPF after 
pharmacological or surgical treatment of GER.(80,81) 
Recent international guidelines suggest regular antacid 
use for all patients with IPF, although the quality of 
evidence is very low.(3,4)
All of the studies evaluating the possible effects of 
pharmacological treatment of GER in patients with IPF 
have been observational, and most have used data 
derived from the placebo arms of clinical trials aimed 
at investigating other drugs.(82-86) To date, there have 
been no clinical trials with an appropriate design and 
an adequate number of volunteers that have evaluated 
the routine use of GER medications in symptomatic 
or asymptomatic patients with IPF.(87)
Evidence
The methodology employed in developing these 
guidelines did not allow us to select articles suitable for 
developing recommendations regarding pharmacological 
treatment of GER in patients with IPF (Figure S5 and 
Table S5).
Recommendation
For patients with IPF, there is insufficient evidence 
to make a recommendation for or against the use of 
pharmacological treatment of GER.
Comments
Studies evaluating the possible effects of 
pharmacological treatment of GER in patients with 
IPF have involved patients who had been randomized 
to the placebo arms of clinical trials of other drugs 
for IPF. (82-86) This strategy introduces a very large 
selection bias, because it is not possible to know why 
pharmacological treatment of GER was prescribed, and 
these patients may therefore not be representative 
of all patients with IPF. Further controlled randomized 
clinical trials of pharmacological treatment of GER are 
needed in order to properly elucidate its effects in 
patients with IPF. Given that pharmacological treatment 
of GER may be associated with potential adverse effects, 
its use should be evaluated on a case-by-case basis 
and should be considered in patients with symptoms 
suggestive of GER or with GER symptoms confirmed 
by ancillary tests.
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QUESTION 6: SHOULD WE RECOMMEND 
THE USE OF N-ACETYLCYSTEINE FOR 
PATIENTS WITH IPF?
N-acetylcysteine (NAC) is a precursor drug to 
glutathione, a water-soluble antioxidant present in 
most cells in the body.(88) A potential contribution of 
oxidative stress to the progression of IPF has led to 
studies being conducted to determine whether the 
use of NAC could restore lung glutathione levels.(88,89) 
Thus, NAC could slow the progression of the disease.
A multicenter double-blind, placebo-controlled study 
evaluated the use of oral NAC plus a corticosteroid 
and azathioprine versus placebo.(11) Participants who 
received NAC plus a corticosteroid and azathioprine 
had a significant reduction in the rate of decline in FVC 
and in DLCO.(11) In contrast, studies of inhaled or oral 
NAC monotherapy versus placebo demonstrated no 
significant differences in the evolution of lung function 
or in other clinical outcomes.(90-92)
Evidence
We selected five systematic reviews with meta-
analyses comparing NAC and placebo with regard to 
mortality, as well as one evaluating reductions in the 
rate of decline in FVC in the treatment of IPF (Figure 
S6 and Table S6).(48,55)
In comparison with placebo, NAC did not reduce 
mortality in patients with IPF (OR = 0.84; 95% CI: 
0.20-4.50).(54) With regard to the reduction in the rate 
of decline in FVC at 12 months, it was not possible 
to estimate the effect of NAC versus that of placebo 
because of the heterogeneity of and high risk of bias 
within the studies selected for the meta-analysis.(48)
Recommendation
For patients with IPF, we suggest not using NAC 
(conditional recommendation; low quality of evidence).
Comments
The lack of effect of NAC on reducing mortality and 
the difficulty in estimating positive effects of NAC on 
reducing the rate of decline in FVC make it unlikely that 
the drug has any beneficial effects on the course of 
IPF. It has been suggested that IPF patient responses 
to the use of NAC may be influenced by TOLLIP gene 
polymorphisms.(93) However, these aspects still require 
further clarification so that robust conclusions can 
be drawn.
QUESTION 7: SHOULD WE RECOMMEND 
THE USE OF CORTICOSTEROIDS FOR 
PATIENTS WITH IPF?
Classical hypotheses regarding the pathogenesis 
of IPF suggest that the onset of the disease is due to 
an inflammatory process, in which proinflammatory 
cytokines released by alveolar macrophages play 
a decisive role.(94,95) In this context, the use of 
corticosteroids would potentially be beneficial to the 
clinical course of patients with IPF. However, the most 
widely accepted hypothesis for the pathogenesis of IPF 
is alveolar epithelial aggression and damage followed by 
release of profibrotic mediators, with abnormal repair, 
myofibroblastic proliferation, and collagen deposition, 
without evident inflammation.(96)
The current concept of IPF was formulated in 2000; 
since then, there have been no controlled clinical trials 
of corticosteroid monotherapy in patients with IPF.(1)
Evidence
Within the literature review date range pre-established 
for these guidelines, it was not possible to find any 
systematic reviews or meta-analyses evaluating the 
effects of corticosteroid monotherapy versus those of 
placebo in the treatment of IPF (Figure S7 and Table S7).
Recommendations
For patients with IPF, there is insufficient evidence 
to make a recommendation for or against the use of 
corticosteroids.
Comments
Although there is no evidence regarding the use 
of corticosteroids in IPF, it is unlikely that studies of 
these drugs in patients with IPF will be conducted, 
because, given the noninflammatory pathogenesis of the 
disease, there appears to be little chance of therapeutic 
success. This recommendation is intended for patients 
with stable IPF. The potential use of corticosteroids in 
patients with acute IPF exacerbations was not analyzed 
in these guidelines.
FINAL CONSIDERATIONS
A summary of the recommendations for the 
pharmacological treatment of IPF is shown in Chart 5. 
Although there is currently no drug that can cure 
IPF, these guidelines suggest that nintedanib and 
pirfenidone be considered for the treatment of the 
disease (conditional recommendation). The evidence 
indicates that these antifibrotic agents are, in fact, 
the only pharmacological treatment options that can 
lead to a reduction in functional decline in IPF. Both 
reduce the rate of decline in FVC, which is a strong 
independent predictor of IPF mortality. However, when 
considering whether or not to use either of these drugs, 
it is essential to evaluate the specifics of each case, 
including the severity of the functional impairment, 
the presence of comorbidities, the concomitant use of 
other drugs (i.e., potential drug interactions), potential 
adverse events, and costs, as well as, in particular, the 
concerns of patients and their families. It should also 
be emphasized that nintedanib and pirfenidone were 
not compared with each other in our guidelines, and 
determining the superiority of one over the other is 
therefore not possible. In addition, the combined use 
of these drugs was not evaluated.
Although the prevalence of GER is high in IPF, we 
found insufficient evidence to define the role of the 
routine use of GER medications in patients with IPF. 
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Again, the decision should be made on the basis of 
the clinical characteristics of each case.
The lack of reliable data does not allow recommendations 
to be made regarding the use of corticosteroids in IPF. 
That does not imply that this category of drugs might 
not be used in other forms of interstitial lung disease, 
such as sarcoidosis and proliferative bronchiolitis.
With regard to the other drugs investigated, it is 
suggested that neither a PDE5 inhibitor nor NAC be 
used (conditional recommendation), and it is strongly 
recommended that endothelin-receptor antagonists 
not be prescribed for patients with IPF.
It should be emphasized that non-pharmacological 
approaches to IPF, including oxygen supplementation, 
pulmonary rehabilitation, immunizations, and lung 
transplantation, were not considered in the development 
of these guidelines. It should also be emphasized that 
the guidelines in question apply only to patients with IPF, 
which means that the results cannot be extrapolated to 
patients with fibrotic lung diseases from other causes.
We believe that the present document represents 
an important tool to be incorporated in the approach 
to patients with IPF, aiming mainly to improve its 
management, as well as aiding in the development 
of public policies related to the disease.
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Yes (suggestion) Conditional Low
3. Should we recommend the use of phosphodiesterase-5 
inhibitors for patients with IPF?
No (suggestion) Conditional Moderate
4. Should we recommend the use of endothelin-receptor 




5. Should we recommend pharmacological treatment of 
gastroesophageal reflux for patients with IPF?
Unknown
Lack of eligible studies for selection
6. Should we recommend the use of N-acetylcysteine for 
patients with IPF?
No (suggestion) Conditional Low
7. Should we recommend the use of corticosteroids for 
patients with IPF?
Unknown
Lack of eligible studies for selection
IPF: idiopathic pulmonary fibrosis.
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